Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.36 |
| ▸ | F13A1 | P00488 | 1/20 | 0.33 |
| ▸ | TGM2 | P21980 | 1/20 | 0.33 |
| ▸ | TGM1 | P22735 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KAT7 | O95251 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4840050 | 0.93 | PARP1 (0.37) | PARP1NR1H2MEN1KMT2AMAPT | |
| SCHEMBL4843363 | 0.93 | PARP1 (0.37) | PARP1NR1H2MEN1KMT2AMAPT | |
| SCHEMBL29318680 | 0.81 | MEN1 (0.42) | HSD17B10MEN1KMT2AALDH1A1 | |
| SCHEMBL4840263 | 0.81 | PARP1 (0.38) | PARP1NR1H2NR1H3HSD17B10MEN1 | |
| SCHEMBL29550324 | 0.81 | PDE8B (0.42) | HSD17B10MEN1KMT2AALDH1A1 | |
| SCHEMBL4406008 | 0.81 | PDE8B (0.42) | HSD17B10MEN1KMT2AALDH1A1 | |
| SCHEMBL29551042 | 0.81 | PDE8B (0.42) | HSD17B10MEN1KMT2AALDH1A1 | |
| SCHEMBL28490941 | 0.79 | PARP1 (0.48) | PARP1NR1H2NR1H3HSD17B10MEN1 | |
| SCHEMBL30111484 | 0.77 | NR1H2 (0.46) | PARP1NR1H2NR1H3HSD17B10MEN1 | |
| SCHEMBL1183970 | 0.77 | NR1H2 (0.46) | PARP1NR1H2NR1H3HSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7384934-B2 | Piperazine substituted aryl benzodiazepines | ELI LILLY AND COMPANY (US) | 2008-06-10 | — | — | US | disclosed |
| EP-1546134-B1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES | LILLY CO ELI (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20060084643-A1 | Piperazine substituted aryl benzodiazepines | ELI LILLY AND COMPANY | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084643-A1 | Piperazine substituted aryl benzodiazepines | GABBR1, GABBR2, GABRA5 | PARP1 2330/4885F13A1 2965/4885TGM2 4137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.